Robert Dee Etherington - Jun 7, 2024 Form 4 Insider Report for Clene Inc. (CLNN)

Role
Chief Executive Officer, Director
Signature
/s/ Jerry Miraglia POA
Stock symbol
CLNN
Transactions as of
Jun 7, 2024
Transactions value $
$0
Form type
4
Date filed
6/10/2024, 04:17 PM
Previous filing
Jul 3, 2023
Next filing
Jul 30, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLNN Stock Options (Right to buy) Award $0 +900K $0.00 900K Jun 7, 2024 Common Stock 900K $0.37 Direct F1
transaction CLNN Stock Options (Right to buy) Award $0 +2.25M $0.00 2.25M Jun 7, 2024 Common Stock 2.25M $0.37 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on June 7, 2024 as an option for 900,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested
F2 This option was granted on June 7, 2024 as an option for 2,250,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs.